Novartis Gains FDA Approval For Cosentyx In Pediatric Hidradenitis Suppurativa

The U.S. FDA approved Novartis' Cosentyx for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa, making it the first IL-17A inhibitor for this younger cohort. The label expansion enlarges Cosentyx's addressable patient population and should provide a modest positive revenue tailwind for Novartis, supporting uptake in pediatric dermatology markets.

Analysis

The U.S. FDA approved Novartis' Cosentyx for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa, making it the first IL-17A inhibitor for this younger cohort. The label expansion enlarges Cosentyx's addressable patient population and should provide a modest positive revenue tailwind for Novartis, supporting uptake in pediatric dermatology markets.